France's Sanofi launches Zika virus vaccine research

Image
AFP Paris
Last Updated : Feb 02 2016 | 3:48 PM IST
French pharmaceutical giant Sanofi announced today that it had begun research and development into a vaccine against the mosquito-borne Zika virus, blamed for causing a surge in brain-damaged babies.
The company said the success of its Sanofi Pasteur vaccines division in developing a vaccine against dengue fever could be "rapidly leveraged" in the fight against Zika.
"Sanofi Pasteur leads the vaccine field for viruses in the same family as Zika virus (ZIKV), with licensed vaccines against yellow fever, Japanese encephalitis and, most recently, dengue," it said in a statement.
It continued that "Sanofi Pasteur's expertise and established R&D and industrial infrastructure for the newly licensed vaccine for dengue, Dengvaxia, can be rapidly leveraged to help understand the spread of ZIKV and potentially speed identification of a vaccine candidate for further clinical development."
The announcement comes a day after the World Health Organisation declared an international emergency over the Zika virus which it last week warned was "spreading explosively" in the Americas.
The UN health body also said a surge in serious birth defects in South America was "strongly suspected" of being caused by the Zika virus.
Brazil has now warned pregnant women to stay away from the Olympics due to open in August in Rio de Janeiro.
"Sanofi Pasteur is responding to the global call to action to develop a Zika vaccine given the disease's rapid spread and possible medical complications," vaccine project head Nicholas Jackson said in the statement.
"In addition to the serious possibility of congenital complications associated with Zika, investigations are also underway to assess another reported connection between Zika and a dangerous neurological disorder," he added.
There is currently no treatment for Zika. The virus is transmitted by the Aedes aegypti mosquito, which also spreads dengue fever, and which is found everywhere in the Americas except Canada and Chile.
WHO has warned that the Americas region could see up to four million Zika cases this year alone.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 02 2016 | 3:48 PM IST

Next Story